HPX

HPX is a biotechnology company focused on developing therapeutic applications of hemopexin (HPX), a naturally occurring plasma protein that binds and neutralizes free heme. The company's primary mission is to address conditions characterized by heme-mediated toxicity, such as sickle cell disease, beta-thalassemia, and other hemolytic disorders. By replenishing hemopexin levels, HPX aims to prevent the inflammatory and oxidative damage caused by free heme in the vasculature. Their research also extends to acute conditions like sepsis and kidney injury where heme plays a pathological role. The company is currently in the pre-clinical stage, advancing its lead recombinant hemopexin candidates toward human trials.